NEW YORK, Dec. 27, 2017 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ALNY, CLDX, ADRO, and ZSAN which can be accessed for free by signing up to http://www.wallstequities.com/registration. Wall Street is holding its breath for the rekindling of mergers and acquisitions across
Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc.'s shares gained 0.58%, closing Tuesday's trading session at $124.68. The stock recorded a trading volume of 407,321 shares. The Company's shares have advanced 11.26% over the previous three months and 233.01% since the start of this year. The stock is trading 41.62% above its 200-day moving average. Additionally, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have a Relative Strength Index (RSI) of 49.91.
On December 18th, 2017, Alnylam Pharma and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis. Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the Agency's evaluation time from 210 to 150 days. Get the full research report on ALNY for free by clicking below at: http://www.wallstequities.com/registration/?symbol=ALNY
On Tuesday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. recorded a trading volume of 781,342 shares. The stock rose 2.82%, ending the day at $2.92. The Company's shares have advanced 0.69% in the past month and 7.35% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.99% and 3.80%, respectively. Furthermore, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 55.02.
On November 30th, 2017, Celldex Therapeutics announced that enrollment has opened in its open-label, Phase-1 study of CDX-1140 in patients with advanced solid tumors. CDX-1140 is a fully human antibody targeted to CD40, a key activator of immune response that is found on dendritic cells, macrophages, and B cells, and is also expressed on many cancer cells. CLDX's complimentary research coverage is a few simple steps away at: http://www.wallstequities.com/registration/?symbol=CLDX
Berkeley, California headquartered Aduro BioTech Inc.'s stock finished the day 3.73% lower at $7.75 with a total trading volume of 382,744 shares. The stock is trading below their 50-day moving average by 8.88%. Shares of the Company, which focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases, have an RSI of 37.96.
On December 13th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $18 a share to $9.50 a share.
On December 20th, 2017, Aduro BioTech announced that the US Patent and Trademark Office has issued a new patent in the Company's portfolio, related to the activation of the STING (Stimulator of Interferon Genes) pathway. US Patent 9,840,533 licensed from Memorial Sloan Kettering, The Rockefeller University, Rutgers, The State University of New Jersey, and University of Bonn covers pioneering composition of matter claims to a broad class of cyclic dinucleotide structures that induce STING-dependent immune responses. Register for your free research report on ADRO at: http://www.wallstequities.com/registration/?symbol=ADRO
Shares in Fremont, California headquartered Zosano Pharma Corp. ended yesterday's session 9.28% lower at $0.59. The stock recorded a trading volume of 779,388 shares. The Company's shares are trading 15.18% below their 50-day moving average. Moreover, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients, have an RSI of 42.84.
On December 15th, 2017, Zosano Pharma announced that Bruce Steel has tendered his resignation from the Board of Directors, effective immediately. Following up on Mr. Steel's resignation, the number of Board of Director seats has been reduced to five. Wall St. Equities' downloadable research report on ZSAN available at: http://www.wallstequities.com/registration/?symbol=ZSAN
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----alnylam-pharma-celldex-therapeutics-aduro-biotech-and-zosano-pharma-300575454.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All